| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 22 | 2022 | 763 | 1.920 |
Why?
|
| Glioblastoma | 14 | 2021 | 255 | 1.740 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 2903 | 1.460 |
Why?
|
| Biomarkers, Tumor | 12 | 2022 | 1464 | 1.380 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 151 | 1.260 |
Why?
|
| Research Design | 8 | 2021 | 594 | 1.230 |
Why?
|
| Glioma | 6 | 2023 | 285 | 1.160 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2022 | 137 | 1.140 |
Why?
|
| Biomarkers | 5 | 2023 | 1718 | 0.980 |
Why?
|
| Data Interpretation, Statistical | 4 | 2021 | 297 | 0.960 |
Why?
|
| Dacarbazine | 10 | 2019 | 102 | 0.930 |
Why?
|
| Models, Statistical | 4 | 2017 | 574 | 0.750 |
Why?
|
| Statistics as Topic | 1 | 2021 | 238 | 0.730 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 2360 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2022 | 2438 | 0.700 |
Why?
|
| Sample Size | 4 | 2017 | 130 | 0.700 |
Why?
|
| Ki-67 Antigen | 3 | 2021 | 64 | 0.680 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 329 | 0.640 |
Why?
|
| Prognosis | 14 | 2021 | 3679 | 0.640 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 124 | 0.620 |
Why?
|
| Receptor, ErbB-2 | 5 | 2022 | 223 | 0.620 |
Why?
|
| Precision Medicine | 4 | 2023 | 395 | 0.560 |
Why?
|
| Clinical Trials as Topic | 4 | 2013 | 1169 | 0.550 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.510 |
Why?
|
| Humans | 60 | 2023 | 86643 | 0.490 |
Why?
|
| Biological Specimen Banks | 1 | 2014 | 65 | 0.480 |
Why?
|
| Neoplasms | 5 | 2023 | 2898 | 0.470 |
Why?
|
| Biomedical Research | 2 | 2017 | 376 | 0.470 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 1204 | 0.470 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 859 | 0.460 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1753 | 0.440 |
Why?
|
| Molecular Targeted Therapy | 2 | 2013 | 266 | 0.420 |
Why?
|
| Female | 35 | 2022 | 44532 | 0.410 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 155 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1313 | 0.400 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 860 | 0.400 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2012 | 176 | 0.390 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 270 | 0.380 |
Why?
|
| Computational Biology | 1 | 2013 | 528 | 0.370 |
Why?
|
| Neurosurgical Procedures | 6 | 2011 | 213 | 0.360 |
Why?
|
| Paraproteinemias | 2 | 2020 | 13 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1961 | 0.330 |
Why?
|
| Lymphoma, Follicular | 2 | 2019 | 70 | 0.330 |
Why?
|
| Aged | 24 | 2020 | 18415 | 0.320 |
Why?
|
| Endpoint Determination | 1 | 2007 | 60 | 0.300 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 1673 | 0.300 |
Why?
|
| Oligodendroglioma | 2 | 2022 | 45 | 0.300 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 6509 | 0.290 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 418 | 0.290 |
Why?
|
| Middle Aged | 25 | 2021 | 25028 | 0.290 |
Why?
|
| Vincristine | 3 | 2022 | 111 | 0.280 |
Why?
|
| Adult | 25 | 2020 | 25648 | 0.280 |
Why?
|
| Young Adult | 15 | 2020 | 5976 | 0.270 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 930 | 0.260 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 299 | 0.260 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2013 | 292 | 0.250 |
Why?
|
| Prospective Studies | 5 | 2023 | 4213 | 0.240 |
Why?
|
| Treatment Outcome | 17 | 2021 | 7993 | 0.230 |
Why?
|
| Meningeal Neoplasms | 1 | 2023 | 61 | 0.230 |
Why?
|
| Meningioma | 1 | 2023 | 60 | 0.230 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 3640 | 0.230 |
Why?
|
| Etoposide | 2 | 2020 | 196 | 0.220 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 384 | 0.220 |
Why?
|
| Prednisone | 2 | 2020 | 258 | 0.220 |
Why?
|
| Male | 25 | 2020 | 40965 | 0.220 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 468 | 0.210 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2021 | 24 | 0.210 |
Why?
|
| Combined Modality Therapy | 10 | 2020 | 1686 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2023 | 359 | 0.200 |
Why?
|
| British Columbia | 1 | 2021 | 7 | 0.200 |
Why?
|
| Neurology | 1 | 2021 | 70 | 0.190 |
Why?
|
| Fluorine Radioisotopes | 1 | 2020 | 25 | 0.190 |
Why?
|
| Cyclin D1 | 1 | 2020 | 83 | 0.180 |
Why?
|
| Rituximab | 1 | 2020 | 116 | 0.180 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2019 | 8 | 0.180 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 138 | 0.170 |
Why?
|
| Internal Medicine | 1 | 2023 | 347 | 0.170 |
Why?
|
| Bortezomib | 1 | 2019 | 76 | 0.170 |
Why?
|
| Monosomy | 1 | 2019 | 12 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 180 | 0.170 |
Why?
|
| Quality of Life | 3 | 2014 | 1585 | 0.170 |
Why?
|
| Haploidy | 1 | 2019 | 31 | 0.170 |
Why?
|
| Capecitabine | 1 | 2019 | 96 | 0.170 |
Why?
|
| Disease Progression | 6 | 2018 | 1531 | 0.170 |
Why?
|
| Astrocytoma | 2 | 2010 | 82 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2019 | 110 | 0.170 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 2705 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2011 | 3362 | 0.160 |
Why?
|
| Computer Simulation | 2 | 2014 | 1078 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 177 | 0.160 |
Why?
|
| Genomics | 2 | 2013 | 720 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 236 | 0.160 |
Why?
|
| Survival Analysis | 3 | 2020 | 1538 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2020 | 272 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 381 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 123 | 0.140 |
Why?
|
| Retrospective Studies | 9 | 2019 | 8489 | 0.140 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 1939 | 0.140 |
Why?
|
| DNA Repair Enzymes | 2 | 2013 | 52 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 425 | 0.140 |
Why?
|
| Mutation | 2 | 2019 | 3968 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 307 | 0.130 |
Why?
|
| Karnofsky Performance Status | 2 | 2011 | 40 | 0.130 |
Why?
|
| Indoles | 3 | 2011 | 318 | 0.130 |
Why?
|
| Survival Rate | 6 | 2019 | 1863 | 0.120 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2011 | 138 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2022 | 2261 | 0.120 |
Why?
|
| Doxorubicin | 3 | 2019 | 295 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 185 | 0.120 |
Why?
|
| DNA Modification Methylases | 1 | 2013 | 25 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1195 | 0.120 |
Why?
|
| Laboratories | 1 | 2013 | 43 | 0.120 |
Why?
|
| Indazoles | 1 | 2013 | 68 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2014 | 103 | 0.110 |
Why?
|
| Logistic Models | 2 | 2014 | 1186 | 0.110 |
Why?
|
| Methylation | 1 | 2013 | 251 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 182 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 865 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2013 | 256 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2012 | 11 | 0.110 |
Why?
|
| Sulfotransferases | 1 | 2012 | 19 | 0.110 |
Why?
|
| Quinazolines | 1 | 2013 | 220 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2011 | 262 | 0.100 |
Why?
|
| Age Factors | 2 | 2019 | 1851 | 0.100 |
Why?
|
| Gliosarcoma | 1 | 2011 | 7 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 279 | 0.100 |
Why?
|
| Ependymoma | 1 | 2011 | 17 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2018 | 1351 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 300 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2011 | 49 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2013 | 2262 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 94 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2013 | 370 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2011 | 85 | 0.100 |
Why?
|
| Inositol | 1 | 2010 | 15 | 0.100 |
Why?
|
| Supratentorial Neoplasms | 1 | 2010 | 10 | 0.100 |
Why?
|
| Gyrus Cinguli | 1 | 2010 | 45 | 0.100 |
Why?
|
| Exotoxins | 1 | 2010 | 20 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2013 | 485 | 0.090 |
Why?
|
| Spinal Neoplasms | 1 | 2010 | 50 | 0.090 |
Why?
|
| Interleukin-13 | 1 | 2010 | 36 | 0.090 |
Why?
|
| Craniotomy | 1 | 2010 | 88 | 0.090 |
Why?
|
| Genes, p16 | 1 | 2010 | 11 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 102 | 0.090 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2010 | 67 | 0.090 |
Why?
|
| Catheters | 1 | 2010 | 74 | 0.090 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 81 | 0.090 |
Why?
|
| Caregivers | 1 | 2011 | 151 | 0.090 |
Why?
|
| Paclitaxel | 2 | 2022 | 460 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 426 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 318 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 301 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2014 | 629 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2010 | 170 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 138 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 318 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 128 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2010 | 329 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 344 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 276 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 348 | 0.080 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 621 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2011 | 1204 | 0.080 |
Why?
|
| Inflammation | 1 | 2013 | 920 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 434 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2022 | 172 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2011 | 374 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 379 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2011 | 628 | 0.070 |
Why?
|
| Bevacizumab | 2 | 2022 | 281 | 0.070 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 584 | 0.070 |
Why?
|
| Adolescent | 6 | 2019 | 8981 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1075 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1376 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 357 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 2426 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1920 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2018 | 678 | 0.060 |
Why?
|
| Lomustine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Procarbazine | 1 | 2022 | 40 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2012 | 3241 | 0.050 |
Why?
|
| International Cooperation | 2 | 2013 | 127 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2012 | 1578 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 303 | 0.050 |
Why?
|
| Risk Factors | 1 | 2011 | 5417 | 0.050 |
Why?
|
| Carboplatin | 1 | 2022 | 286 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 162 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2021 | 103 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2014 | 912 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2020 | 68 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2207 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2011 | 265 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 307 | 0.040 |
Why?
|
| Vinblastine | 1 | 2019 | 108 | 0.040 |
Why?
|
| Bleomycin | 1 | 2019 | 98 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2010 | 2767 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2011 | 782 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 250 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2023 | 572 | 0.040 |
Why?
|
| Karyotype | 1 | 2019 | 33 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2011 | 790 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2018 | 74 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 88 | 0.040 |
Why?
|
| Methotrexate | 1 | 2019 | 249 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2011 | 328 | 0.040 |
Why?
|
| Genes, myc | 1 | 2018 | 39 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 1384 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 170 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 159 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 556 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 722 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 916 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 5210 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 387 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 167 | 0.040 |
Why?
|
| Alleles | 1 | 2020 | 1128 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 144 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 580 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 552 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 229 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2011 | 3612 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 70 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2818 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 21 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2013 | 274 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 55 | 0.030 |
Why?
|
| Checklist | 1 | 2013 | 57 | 0.030 |
Why?
|
| Mice | 3 | 2012 | 11352 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2013 | 98 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 361 | 0.030 |
Why?
|
| Animals | 4 | 2014 | 26582 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 162 | 0.030 |
Why?
|
| Sulfatases | 1 | 2012 | 4 | 0.030 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2012 | 21 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 602 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2011 | 35 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2357 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2011 | 35 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2011 | 72 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 2271 | 0.020 |
Why?
|
| Acetylation | 1 | 2011 | 121 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 63 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 23 | 0.020 |
Why?
|
| Choline | 1 | 2010 | 23 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2011 | 144 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2010 | 90 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2010 | 44 | 0.020 |
Why?
|
| Neuronavigation | 1 | 2010 | 21 | 0.020 |
Why?
|
| Software | 1 | 2014 | 654 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 303 | 0.020 |
Why?
|
| Risk Management | 1 | 2010 | 43 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2010 | 61 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2011 | 157 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 166 | 0.020 |
Why?
|
| Perfusion | 1 | 2010 | 203 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2601 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 201 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 204 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 289 | 0.020 |
Why?
|
| Sulfites | 1 | 2009 | 26 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2010 | 151 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 969 | 0.020 |
Why?
|
| Microsurgery | 1 | 2010 | 84 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 458 | 0.020 |
Why?
|
| Child | 2 | 2011 | 6927 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 1041 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 172 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 927 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 679 | 0.020 |
Why?
|
| Serine | 1 | 2009 | 99 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 776 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 207 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 421 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 311 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2008 | 27 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 894 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 557 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1540 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 639 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 455 | 0.020 |
Why?
|
| Emotions | 1 | 2011 | 341 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2010 | 548 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1805 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2009 | 1106 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 1749 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1991 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 663 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1019 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 3046 | 0.020 |
Why?
|
| Apoptosis | 1 | 2011 | 1683 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1197 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 2501 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2216 | 0.010 |
Why?
|
| United States | 1 | 2013 | 6672 | 0.010 |
Why?
|